Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.63 USD | +1.24% | -2.98% | +5.16% |
Financials (USD)
Sales 2024 * | 94.02M | Sales 2025 * | 72.9M | Capitalization | 110M |
---|---|---|---|---|---|
Net income 2024 * | -24M | Net income 2025 * | -43M | EV / Sales 2024 * | 1.17 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1.51 x |
P/E ratio 2024 * |
-5.63
x | P/E ratio 2025 * |
-4.31
x | Employees | 121 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.81% |
Latest transcript on CytomX Therapeutics, Inc.
1 day | +1.24% | ||
1 week | -2.98% | ||
1 month | -25.23% | ||
3 months | +6.54% | ||
6 months | +48.18% | ||
Current year | +5.16% |
Managers | Title | Age | Since |
---|---|---|---|
Sean McCarthy
CEO | Chief Executive Officer | 57 | 10-11-30 |
Chris Ogden
DFI | Director of Finance/CFO | 40 | 21-08-01 |
Marcia Belvin
CTO | Chief Tech/Sci/R&D Officer | 57 | 17-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
James Meyers
BRD | Director/Board Member | 58 | 18-12-19 |
Elaine Jones
BRD | Director/Board Member | 69 | 14-11-30 |
Sean McCarthy
CEO | Chief Executive Officer | 57 | 10-11-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-30 | 1.63 | +1.24% | 381,991 |
24-04-29 | 1.61 | +1.26% | 399,614 |
24-04-26 | 1.59 | -0.63% | 249,227 |
24-04-25 | 1.6 | -1.84% | 286,317 |
24-04-24 | 1.63 | -2.98% | 350,911 |
Delayed Quote Nasdaq, April 30, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+5.16% | 110M | |
-3.46% | 102B | |
+1.41% | 96.09B | |
+2.13% | 22.28B | |
-15.84% | 21.4B | |
-10.00% | 18.14B | |
-39.98% | 17.02B | |
-14.65% | 16.09B | |
+4.39% | 13.83B | |
+31.35% | 11.97B |
- Stock Market
- Equities
- CTMX Stock